Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia

Atherosclerosis

Volumn 119, Issue 2, 1996, Pages 203-213

  Naoumova, R P ^a   Marais, A D ^b   Mountney, J ^b   Firth, J C ^b   Rendell, N B ^a   Taylor, G W ^a   Thompson, G R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Atorvastatin; Cholesterol biosynthesis; Familial hypercholesterolaemia; Plasma mevalonic acid; Pravastatin; Simvastatin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVALONIC ACID; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0030050055     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05649-1     Document Type: Article

References (41)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
2. Illingworth DR. How effective is drug therapy in heterozygous familial hypercholesterolaemia? Am J Cardiol 1993;72:540-580.
3. Illingworth DR, Sexton GJ. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest 1984;74:1972-1978.
4. Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, Tobert JA, Bacon SR, Bolinese JA, Frost PH, Lampkin GE. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter study. Ann Intern Med 1987;107:609-615.
5. Illingworth DR, Bacon S, Pappu AS, Sexton GJ. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1992;96:53-64.
6. O'Malley JP, Illingworth DR. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism, 1990;39:150-154.
7. De Knijff P, Stalenhoef AFH. Mol MJTM, Leuven JAG Smith J, Erkelens DW, Schouten J, Frants RR. Havekes LM. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1990;83:89-97.
8. Carmena R, Roederes G, Mailloux H, Lussier-Cacan S. Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 1993;42:895-901.
9. Jeenah M, September W, Graadt van Roggen FG, de Villiers W, Steftel H, Marais AD. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1993;98:51-58.
10. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Wurm M, Bard J-M, Fruchart J-C, Stein Y. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor Fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993:87(Suppl III):III-35-III-44.
11. Hobbs HH, Leitersdorf E, Goldstein JL, Brown MS. Russell DW. Multiple crm mutations in familial hypercholesterolemia. Evidence for 13 alleles, including 4 deletions. J Clin Invest 1988;81:909-917.
12. Parker TS, McNamara DJ, Brown CD, Kolb R, Ahrens EH Jr, Alberts AW, Tobert J, Chen J, De Schepper PJ. Plasma mevalonate as a measure of cholesterol biosynthesis in man. J Clin Invest 1984;74:795-804.
13. Pappu AS, Illingworth DR. Contrasting effects of lovastatin and cholestyramine on low-density cholesterol and 24-h urinary mevalonate excretion in patients with heterozygous familial hypercholesterolaemia. J Lab Clin Med 1989;114:554-562.
14. Parker TS, McNamara DJ, Brown C, Garrigan D, Kolb R, Batwin H, Ahrens EH Jr. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA 1982;79:3037-3041.
15. Scoppola A, Maher VMG, Thompson GR, Rendell NB, Taylor GW. Quantitation of plasma mevalonic acid using gas chromatography electron capture mass spectrometry. J Lipid Res 1991;32:1057-1060.
16. Yoshida T, Houda A, Tanaka N, Matsuzaki Y, He B, Osuga T, Kobajashi N, Ozawa K, Miyazaki H. Simultaneous determination of mevalonate and 7α-hydroxy-cholesterol in human plasma by gas chromatography mass spectrometry as indices of cholesterol and bile acid biosynthesis. J Chromatogr 1993;613:185-193.
17. Jones PJH, Pappu AS, Illingworth DR, Leitch CA. Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis. Eur J Clin Invest 1992;22:609-613.
18. Pfohl M, Naoumova RP, Klass C, Knisel W, Jakober B Risler T, Thompson GR. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res 1994;35:1946-1955.
19. Warnick ER, Albers JJ. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 1978;19:65-76.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
21. Kotze MJ, De Valliers WJS, Steyn K, Kriek JA, Marais AD, Langenhoven E, Herbert JS, Graadt Van Roggen JF, Van der Westhuyzen DR, Coetzee GA. Phenotypic variation among familial hypercholesterolemic heterozygotes for either one or two Afrikaner founder LDL receptor mutations. Arteriosclerosis Thromb 1993;13:1460-1468.
22. Tybjaerg-Hansen A, Gallagher J, Vincent J, Houlston R, Talmud P, Dunning AM, Seed M, Hamsten A, Humphries SE, Myant NB. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 1990;80:235-242.
23. Gylling H, Miettinen TA. Serum non-cholesterol sterols related to cholesterol metabolism in familial hypercholesterolaemia. Clin Chim Acta 1988;178:41-50.
24. Elmberger PG, Kalen A, Lund E, Reihner E, Eriksson M, Berglund L, Angelin B, Dallner G. Effect of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991;32:935-940.
25. Kempen HJM, Gevers Leuven JA, van der Voort HA, de Knijff P, Havekes L. Lathosterol level in plasma is elevated in type III hyperlipoproteinemia but not in Type III subjects with apolipoprotein E2/2 phenotype, nor in Type IIa or IIb hyperlipoproteinemia. Metabolism, 1991;40: 231-235.
26. Illingworth DR, Pappu AS, Bacon SP. Metabolic and clinical effects of mevinolin in familial hypercholesterolemia. In: Fidge NH and Nestel PJ. (eds). Atherosclerosis VII. Amsterdam: Elsevier, 1986;611-614.
27. Hagemenas FC, Pappu AS, Illingworth DR. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1990;20:150-157.
28. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, Jones PH, Haber ME, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis Thromb Vasc Biol 1995;15:678-682.
29. Alberts AW. HMG-CoA reductase inhibitors - the development. Atherosclerosis Rev 1988;18:123-131.
30. Bocan TMA, Ferguson E, McNally W, Uhlendorf PD Mueller SB, Dehart P, Sliskovic DR, Roth BD, Krause BR, Newton RS. Hepatic and non-hepatic synthesis and tissue distribution following administration of a liver selective HMG CoA reductase inhibitor. CI-981: comparison with selected HMG CoA reductase inhibitors. Biochim Biophys Acta 1992;1123:133-144.
31. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994;343:1554-1555.
32. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-1582.
33. Clarke CF, Fogelman AM, Edwards PW. Transcriptional regulation of the 3-hydroxy-3 methyl glutaryl coenzyme A reductase gene in rat liver. J Biol Chem 1985;260:14 363-14 367.
34. Reihner RD, Stahlberg D, Rudling M, Ewerth S, Bjorkhem I, Einarsson K, Angelin B. Effects of pravastatin (SQ 31,000) on hepatic cholesterol metabolism in man. N Engl J Med 1990;323:224-228.
35. Karayan L, Qiu S, Betard C, Dufour R, Roederer G, Minnich A, Davignon J, Genes J Jr. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolaemia due to the 10 kb deletion ('French Canadian mutation') of the EDL receptor gene. Arteriosclerosis Thromb 1994;14:1258-1263.
36. Vuorio AF, Ojala J-P, Sarna S, Turtola H, Tikkanen MJ, Kontula K, Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. J Intern Med 1995;237: 43-48.
37. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park J-S, Cole T, Schaefer EJ. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995;113:157-166.
38. Watts GF, Naoumova R, Cummings MH, Thompson GR. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidaemic subjects. Metabolism 1995;44:1052-1057.
39. Watts GF, Cummings MH, Umbleby M, Quincy JR, Naoumova R, Thompson GR, Sönksen PH. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur J Clin Invest 1995;25:559-567.
40. Khan B, Wilcox HG, Heimberg M. Cholesterol is required for secretion of very-low-density lipoprotein by rat liver. Biochem J 1989;259:807-816.
41. Auerbach BJ, Krause BR, Bisgaier CL, Newton RS. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis 1995;115:173-180.